HASBROUCK HEIGHTS, N.J., Dec. 16, 2008 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced new results from a recently completed multi-center U.S. clinical study of NX-1207, the Company’s innovative investigational drug for benign prostatic hyperplasia (BPH). The evidence indicates that NX-1207 can markedly reduce the incidence of nocturia, a particularly bothersome symptom of nighttime urination associated with BPH. After 90 days, subjects treated with a therapeutic dose of NX-1207 had a mean 49% reduction in nocturia symptoms, which was statistically significant compared to baseline (p less than .001).
